Literature DB >> 16893697

Frequency and outcomes of acute renal failure following thoracic aortic stent-graft placement.

Holger Eggebrecht1, Frank Breuckmann, Stefan Martini, Dietrich Baumgart, Ulf Herold, Peter Kienbaum, Jürgen Peters, Heinz Jakob, Raimund Erbel, Rajendra H Mehta.   

Abstract

We assessed the incidence, correlates, and outcomes of acute renal failure (ARF) after thoracic aortic stent-graft placement. Postprocedural ARF is an inherent complication of catheter-based interventional procedures that use intra-arterial contrast agents and has adverse effects on short- and long-term outcomes. However, few data exist on the incidence, predictors, and outcomes of ARF after thoracic aortic stent-graft placement. We analyzed data of 97 patients (64.4 +/- 11.6 years of age; 73% men) who underwent thoracic aortic stent-graft placement from July 1999 to October 2005. Postprocedural ARF was defined as an increase > or = 25% and/or > or = 0.5 mg/dl in preprocedural serum creatinine at 48 hours after the procedure. Baseline estimated glomerular filtration rate was 65 +/- 24 ml/min/1.73 m2. Chronic kidney disease (glomerular filtration rate < or = 60 ml/min/1.73 m2) at baseline was present in 45% of patients. During the stent-graft procedure, patients received 307 +/- 188 ml of nonionic contrast medium. Postprocedural ARF occurred in 33 patients (34%), and 3 required dialysis. Multivariable analysis identified American Society of Anesthesiologists class > 3 (odds ratio 5.53, 95% confidence interval 1.71 to 17.85, p = 0.004) and duration of the stent-graft procedure (odds ratio 1.01, 95% confidence interval 1.001 to 1.014, p = 0.022) as independent predictors of postprocedural ARF. Compared with patients without ARF, those with ARF had markedly higher 30-day (18.2 +/- 6.7% vs 1.6 +/- 1.6%, p = 0.0022) and 1-year (35.2 +/- 8.6% vs 10.1 +/- 3.9%, p = 0.001) mortality. In conclusion, postprocedural ARF is a frequent complication of thoracic aortic stent-graft placement and has a significant adverse effect on 30-day and 1-year survival. Baseline factors identified in our study as associated with increased risk of ARF may facilitate a comprehensive informed consent process by way of patient education. In addition, identification of an at-risk subset may allow modification of reversible periprocedural factors that may help decrease postprocedural ARF.

Entities:  

Mesh:

Year:  2006        PMID: 16893697     DOI: 10.1016/j.amjcard.2006.02.052

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Cohort comparison of thoracic endovascular aortic repair with open thoracic aortic repair using modern end-organ preservation strategies.

Authors:  Dean J Arnaoutakis; George J Arnaoutakis; Christopher J Abularrage; Robert J Beaulieu; Ashish S Shah; Duke E Cameron; James H Black
Journal:  Ann Vasc Surg       Date:  2015-03-07       Impact factor: 1.466

2.  Relationship between acute kidney injury before thoracic endovascular aneurysm repair and in-hospital outcomes in patients with type B acute aortic dissection.

Authors:  Hong-Mei Ren; Xiao Wang; Chun-Yan Hu; Bin Que; Hui Ai; Chun-Mei Wang; Li-Zhong Sun; Shao-Ping Nie
Journal:  J Geriatr Cardiol       Date:  2015-05       Impact factor: 3.327

3.  The risk of renal function deterioration in abdominal aortic stent graft patients with and without previous kidney function failure - an analysis of risk factors.

Authors:  Tomasz Urbanek; Grzegorz Biolik; Wojciech Zelawski; Beata Hapeta; Maciej Jusko; Waclaw Kuczmik
Journal:  Pol J Radiol       Date:  2020-12-15

4.  A New Era of Diagnosis and Therapy in Acute Aortic Syndromes: The Mainz-Essen Experience (Part II)-Management and Outcomes.

Authors:  Eduardo Bossone; Riccardo Gorla; Brigida Ranieri; Valentina Russo; Heinz Jakob; Raimund Erbel
Journal:  Aorta (Stamford)       Date:  2021-12-28

5.  Risk factors and early outcomes of acute renal injury after thoracic aortic endograft repair for type B aortic dissection.

Authors:  Songyuan Luo; Huanyu Ding; Jianfang Luo; Wei Li; Bing Ning; Yuan Liu; Wenhui Huang; Ling Xue; Ruixin Fan; Jiyan Chen
Journal:  Ther Clin Risk Manag       Date:  2017-08-17       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.